These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 23797151)

  • 1. Rechallenge with mTOR inhibitors in metastatic renal cell carcinoma patients who progressed on previous mTOR inhibitor therapy.
    Maj-Hes A; Medioni J; Scotte F; Schmidinger M; Kramer G; Combe P; Gornadha Y; Elaidi R; Oudard S
    Oncology; 2013; 85(1):8-13. PubMed ID: 23797151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Harshman LC; Kroeger N; Rha SY; Donskov F; Wood L; Tantravahi SK; Vaishampayan U; Rini BI; Knox J; North S; Ernst S; Yuasa T; Srinivas S; Pal S; Heng DY; Choueiri TK
    Clin Genitourin Cancer; 2014 Oct; 12(5):335-40. PubMed ID: 24787966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.
    Bitting RL; Healy P; Creel PA; Turnbull J; Morris K; Wood SY; Hurwitz HI; Starr MD; Nixon AB; Armstrong AJ; George DJ
    Clin Genitourin Cancer; 2014 Aug; 12(4):241-50. PubMed ID: 24685058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices.
    Jonasch E; Signorovitch JE; Lin PL; Liu Z; Culver K; Pal SK; Scott JA; Vogelzang NJ
    Curr Med Res Opin; 2014 Oct; 30(10):2041-50. PubMed ID: 24983741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma.
    Li S; Kong Y; Si L; Chi Z; Cui C; Sheng X; Guo J
    BMC Cancer; 2014 May; 14():376. PubMed ID: 24886512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI.
    Park K; Lee JL; Park I; Park S; Ahn Y; Ahn JH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
    Med Oncol; 2012 Dec; 29(5):3291-7. PubMed ID: 22460837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors.
    Weikert S; Kempkensteffen C; Busch J; Johannsen M; Grünwald V; Zimmermann K; Flörcken A; Westermann J; Weinkauf L; Miller K; Keilholz U
    World J Urol; 2013 Aug; 31(4):805-9. PubMed ID: 21512806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.
    Di Lorenzo G; Buonerba C; Federico P; Rescigno P; Milella M; Ortega C; Aieta M; D'Aniello C; Longo N; Felici A; Ruggeri EM; Palmieri G; Imbimbo C; Aglietta M; De Placido S; Mirone V
    Eur Urol; 2010 Dec; 58(6):906-11. PubMed ID: 20884115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study.
    Guo J; Huang Y; Zhang X; Zhou F; Sun Y; Qin S; Ye Z; Wang H; Jappe A; Straub P; Pirotta N; Gogov S
    BMC Cancer; 2013 Mar; 13():136. PubMed ID: 23514360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer.
    Powles T; Wheater M; Din O; Geldart T; Boleti E; Stockdale A; Sundar S; Robinson A; Ahmed I; Wimalasingham A; Burke W; Sarker SJ; Hussain S; Ralph C
    Eur Urol; 2016 Mar; 69(3):450-6. PubMed ID: 26364551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Community Oncology Setting.
    Vogelzang NJ; Hackshaw MD; Hutson TE; Bhowmik D; Yap M; Rembert D; Jonasch E
    Clin Genitourin Cancer; 2015 Jun; 13(3):210-7. PubMed ID: 25498215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implications.
    Danesi R; Boni JP; Ravaud A
    Cancer Treat Rev; 2013 Nov; 39(7):784-92. PubMed ID: 23375248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Everolimus vs. temsirolimus for advanced renal cell carcinoma: use and use of resources in the US Oncology Network.
    Vogelzang NJ; Bhor M; Liu Z; Dhanda R; Hutson TE
    Clin Genitourin Cancer; 2013 Jun; 11(2):115-20. PubMed ID: 23063578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma.
    Pal SK; Figlin RA
    Target Oncol; 2011 Mar; 6(1):5-16. PubMed ID: 21484496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S; Bjelogrlic SK
    J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Everolimus for the treatment of advanced renal cell carcinoma.
    Amato R
    Expert Opin Pharmacother; 2011 May; 12(7):1143-55. PubMed ID: 21470068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity.
    Bellmunt J; Pons F; Foreshew A; Fay AP; Powles T; Porta C; Bracarda S; Lampron ME; Cerbone L; Sternberg CN; Hutson TE; Choueiri TK
    Clin Genitourin Cancer; 2014 Aug; 12(4):262-9. PubMed ID: 24795159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma.
    Kuroshima K; Yoshino H; Okamura S; Tsuruda M; Osako Y; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M; Enokida H
    Cancer Sci; 2020 May; 111(5):1607-1618. PubMed ID: 32232883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mTOR inhibitors in advanced renal cell carcinoma.
    Voss MH; Molina AM; Motzer RJ
    Hematol Oncol Clin North Am; 2011 Aug; 25(4):835-52. PubMed ID: 21763970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) rechallenge for patients with metastatic renal cell carcinoma after treatment failure using both VEGFR-TKI and mTOR inhibitor.
    Park I; Lee JL; Ahn JH; Lee DH; Lee KH; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H
    Cancer Chemother Pharmacol; 2015 May; 75(5):1025-35. PubMed ID: 25776906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.